An activating mutation in JAK2 which involves a valine to phenylalanine substitution JAK2V617F was first identified in 2005 and is the most prevalent mutation in MPN, found in 95% of PV, and in more than 50% of PMF and ET [1,13,14,15,16]. Here, JAK2 is linked to myeloproliferative neoplasm.